BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Sells $46,640.00 in Stock
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $5.83, for a total value of $46,640.00. Following the transaction, the director now owns 572,754 shares in the company, valued at approximately $3,339,155.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ BDSI opened at $5.80 on Friday. The firm has a market cap of $519.23 million, a P/E ratio of -7.95 and a beta of 0.39. The company has a current ratio of 2.34, a quick ratio of 2.09 and a debt-to-equity ratio of 0.88. BioDelivery Sciences International, Inc. has a 1-year low of $2.80 and a 1-year high of $6.12. The business’s 50 day moving average is $5.06 and its 200-day moving average is $4.56.
BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative return on equity of 0.85% and a negative net margin of 34.73%. The firm had revenue of $29.68 million for the quarter, compared to analyst estimates of $25.30 million. Analysts forecast that BioDelivery Sciences International, Inc. will post -0.05 EPS for the current year.
A number of brokerages have recently weighed in on BDSI. ValuEngine upgraded BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 29th. William Blair reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Tuesday, September 17th. Finally, BidaskClub lowered BioDelivery Sciences International from a “strong-buy” rating to a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $6.20.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
See Also: Arbitrage
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.